Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/C21orf59_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/C21orf59_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/C21orf59_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/C21orf59_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/C21orf59_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/C21orf59_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
C21orf59 | SNV | Missense_Mutation | rs761867633 | c.494N>A | p.Arg165His | p.R165H | P57076 | protein_coding | deleterious(0.04) | probably_damaging(0.932) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
C21orf59 | SNV | Missense_Mutation | rs771639961 | c.652G>A | p.Ala218Thr | p.A218T | P57076 | protein_coding | deleterious(0.01) | benign(0.169) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
C21orf59 | SNV | Missense_Mutation | rs758717431 | c.479C>T | p.Pro160Leu | p.P160L | P57076 | protein_coding | deleterious(0.01) | possibly_damaging(0.621) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
C21orf59 | SNV | Missense_Mutation | rs754390813 | c.259N>A | p.Gly87Arg | p.G87R | P57076 | protein_coding | tolerated(0.09) | probably_damaging(0.951) | TCGA-BG-A221-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C21orf59 | SNV | Missense_Mutation | novel | c.836N>C | p.Phe279Ser | p.F279S | P57076 | protein_coding | deleterious(0) | possibly_damaging(0.719) | TCGA-DF-A2KY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
C21orf59 | SNV | Missense_Mutation | novel | c.481T>C | p.Tyr161His | p.Y161H | P57076 | protein_coding | tolerated(1) | benign(0.005) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
C21orf59 | SNV | Missense_Mutation | novel | c.657G>C | p.Lys219Asn | p.K219N | P57076 | protein_coding | deleterious(0) | probably_damaging(0.965) | TCGA-EO-A3AS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C21orf59 | deletion | Frame_Shift_Del | | c.246delN | p.Lys82AsnfsTer27 | p.K82Nfs*27 | P57076 | protein_coding | | | TCGA-AP-A0LS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
C21orf59 | SNV | Missense_Mutation | novel | c.445N>T | p.Ala149Ser | p.A149S | P57076 | protein_coding | deleterious(0.03) | possibly_damaging(0.831) | TCGA-BD-A2L6-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
C21orf59 | SNV | Missense_Mutation | rs370327238 | c.697N>G | p.Ile233Val | p.I233V | P57076 | protein_coding | tolerated(1) | benign(0.001) | TCGA-DD-A1EJ-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | III/IV | Targeted Molecular therapy | sorafenib | PD |